BioSpace News Archive

Willow Biosciences Inc. is pleased to announce that it has completed a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow’s cannabigerol.

Company prepares for U.S. IDE clinical trial of its novel metal-free frame designed to reduce complications and preserve long-term treatment options

The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient-focused healthcare

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting at two upcoming virtual investor events in April.

Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its preclinical research will be highlighted during an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Former COO at La Jolla Institute for Immunology to Help Drive R&D Opportunities for AIMS™ Drug Development and Discovery Technology, Including Collaboration Agreements

A coalition of 60 top hospitals and health care institutions have joined forces in a nationwide campaign to encourage adults to get vaccinated against COVID-19.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported its cash position as of March 31, 2021, and provided an operational update.